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Background: Breast cancer is the most frequent oncological disease among women. Estrogens are known to play
an important role in breast cancer development. Recognition of the relationship between polymorphisms within
estrogen metabolizing genes and conventional prognostic factors of breast cancer might improve our knowledge
on individualized breast cancer prognosis. Therefore, we aimed to investigate possible associations between
germline genetic polymorphisms within GSTM1, GSTT1, GSTP1, SULT1A1 and UGT1A1 genes and breast cancer
clinicopathological characteristics together with disease progression.
Methods: Our study involved 80 young (younger than 50 years of age) breast cancer patients. PCR-based
Restriction Fragment Length Polymorphism (RFLP) assay was used to determine GSTP1 and SULT1A1 genotypes.
GSTM1 and GSTT1 null genotypes were detected by multiplex PCR. UGT1A1 polymorphism was investigated with
microsatellite analysis. Relationships between genotypes and breast cancer clinicopathological features along
with disease progression were estimated by Pearson‘s Chi-square test. Logistic regression analyses were
performed to estimate the odds ratios associating different genotypes with clinicopathological characteristics
and disease progression.
Results: The study showed individuals with GSTT1 null genotype to have approximately 3.5 times higher risk for
breast cancer progression than those with wild type genotype (OR = 3.472, 95% CI 1.043-11.559, P = 0.043).
Moreover, SULT1A1 G638A AA genotype significantly increased the chances of HER2 molecular subtype breast
cancer when compared to GG genotype (OR = 19.971, 95% CI 1.716-232.480, P = 0.017). Heterozygotes for GSTP1
A313G genotype were more likely to have positive lymph nodes in comparison to AA genotype carriers (OR = 2.803,
95% CI 1.049-7.487, P = 0.040). No significant correlation was determined for UGT1A1 A(TA)nTAA and GSTM1 +/-
polymorphism alone or combined GTTT1 null and GSTM1 null genotype.
Conclusions: Conclusively, our findings suggest that GSTT1 null genotype and SULT1A1 G638A AA genotype could
be uselful genetic markers for breast cancer prognosis. Further analyses on larger sample size are required to
highlight the effect of GSTP1 G allele on breast cancer prognosis.
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Breast cancer (BC) is the most frequent oncological dis-
ease among women. It is widely accepted that prolonged
exposure to estrogens and their oxidative metabolites
play an important role in BC developement. The carcino-
genic effect of estrogens is thought to manifest in part
through the ability of intermediate estrogen metabolites to
form superoxide radicals and depurinating adducts that
damage DNA [1,2]. Genetic polymorphisms in low pene-
trance genes, involved in estrogen production and metab-
olite elimination, affect the level of estrogens in breast
tissue. Although many studies have shown associations
between polymorphisms within these genes and BC risk,
only a few have elucidated their effect on clinicopathologi-
cal features of breast tumors. Those findings are believed
to improve our knowledge on personalized BC prognosis.
Genes GSTM1, GSTT1, GSTP1, SULT1A1 and UGT1A1
encode for enzymes which have the ability to inactivate
estrogen metabolites and remove them from the target
tissues. The efficiency of estrogen metabolism depends on
interindividual genetic variations, polymorphisms, within
these genes.
Glutathione S-transferases (GSTs) are a superfamily of
enzymes which catalyze the conjugation of glutathione
to a variety of chemicals, including estrogen metabolites,
making them more water-soluble and easier to excrete.
In such a way they decrease oxidative stress generated
during estrogen metabolism. There are seven human
cytosolic GSTs designated GST Alpha, Mu, Pi, Sigma,
Omega, Theta, and Zeta [3]. GSTM1, GSTT1 and GSTP1
have been the most commonly studied.
GSTM1 gene includes a deletion polymorphism which
frequently affects both alleles. Deletion polymorphism in
homozygous state (GSTM1 null) results in the absence
of the enzyme. GSTT1 gene also has a deletion poly-
morphism. Homozygotes for the null allele of GSTT1
lack the respective enzyme. The GSTP1 gene contains
several polymorphisms, including adenine to guanine
transition at nucleotide 313 (A313G) which results in
isoleucine to valine substitution in codon 105. The sub-
stitution is located in close proximity to the hydrophobic
substrate-binding site and was shown to decrease the
enzyme’s activity and affinity for electrophilic substrates
but not for glutathione [4].
Sulfo-transferases (SULTs) are also involved in inactiva-
tion of estrogens by sulfating them to water-soluble me-
tabolites. The most common polymorphism of SULT1A1
is Arg213His resulting from G to A transition at nucleo-
tide 638. It was shown the His amino acid is associated
with lower enzyme activity and lower stability than the
wild-type amino acid [5].
UDP-glucuronosyltransferases (UGTs) catalyze the con-
jugation of glucuronic acid to a variety of compounds in-
cluding estrogens and their metabolites. One of the mostcommon genetic variant of UGT1A1 is a dinucleotide
repeat in the promoter region of the gene. The wild type
allele consists of six TA repeats while the variant allele
has seven repeats in the A(TA)nTAA motif. The seven
repeat allele is known to be associated with decreased
gene expression in comparison to the wild type allele
[6]. The (TA)5 and (TA)8 alleles are rare.
The aim of this study was to examine possible associa-
tions between germline genetic polymorphisms in estrogen
metabolizing genes and breast cancer clinicopathological
features together with disease progression.
Methods
Study population
A group of 80 young (≤50 years of age) premenopausal
female patients, diagnosed with stage I-II BC was col-
lected. Women, who had additional cancer of any
other location, were excluded from the study. Patient
enrolment started in 2005 and follow-up was complete
until 2012 12 31. Blood samples were collected restrospec-
tively during the treatment. The research was approved by
Kaunas Regional Biomedical Research Ethics Committee
(protocol number BE-2-13) and conducted at the Hospital
of Lithuanian University of Health Sciences, Kaunas
Clinics. Informed consent was obtained from every
participant.
Clinicopathological data was collected from medical
records for the analysis of differences among genotypes.
Tumor estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2
(HER2) status had been determined immunohistochemi-
cally. HER2 was considered positive when imunohisto-
chemically detected HER2 (3+) or (2+) amplification status
was confirmed by positive Silver in Situ Hybridization.
Tumour receptor status determined the choice of adjuvant
therapy for clinicians according to approved prognostic and
predictive breast cancer factors and following guidelines for
breast cancer treatment at the time.
Most of the studied BC patients (85%) had negative
stromal lymphocyte infiltration. Almost half of the cases
(48.8%) had positive lymph node involvement. Majority
of the tumours (68.8%) were well to moderately differenti-
ated (G1 or G2). Approximately half of the studied BC pa-
tients were positive for estrogen (51.2%) and progesterone
(46.3%) receptors, while HER2 overexpression was de-
termined only in 22.5% of tumors. The majority of the
patients (47.5%) had luminal A tumor subtype. Triple
negative, luminal B, HER2 molecular subtypes were ob-
served in 30%, 12.5% and 10% of cases, respectively.
Most of the tumours (63.8%) were not larger than 2 cm.
During a follow-up period (of at least 2 years) 27.5% of
patients were documented with a disease progression.
Local and systemic disease spread (excluding contralat-
eral BC) was considered to be disease progression.
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Genomic DNA was isolated from peripheral blood leu-
kocytes using a commercially available DNA extraction
kit (ThermoFisher Scientific Baltics, Lithuania) utilizing
silica-based membrane technology.
Homozygous deletions of GSTT1 and GSTM1 genes
were detected by multiplex polymerase chain reaction
(PCR). The reaction conditions were described by Altayli
and colleagues [7]. Albumin gene (ALB) was used as in-
ternal positive control. Primer sequences (Table 1) for the
studied genes and ALB have been previously described by
Ambrosone et al. [8] and Altayli et al. [7], respectively.
The absence of GSTM1 or GSTT1 amplification indicated
null genotypes.
A313G polymorphism in GSTP1 gene was determined
by PCR-RFLP (Restriction Fragment Length Polymorph-
ism) method. DNA fragments were amplified for 37 cycles
with annealing at 63°C. Primer sequences (Table 1) have
been previously described by Zhao and coauthors [9].
Amplification products were then subjected to Alw26I re-
striction enzyme digestion where presence of the G allele
resulted in the generation of 148 and 41 bp fragments,
while the A allele remained uncut.
SULT1A1 G638A polymorphism was investigated using
PCR-RFLP. Reaction conditions and primer sequences
were designed by Han et al. [10]. The digestion with HhaI
yielded 166 and 167 bp fragments in the presence of wild
type allele.
All the above PCR products were separated by electro-
phoresis in 2% agarose gel, stained with ethidium brom-
ide (Figure 1A,B,C).
In order to analyze TA repeats in the promoter of
the UGT1A1 gene PCR reaction was performed with
35 cycles of amplification and with annealing at 56 C.Table 1 Primer sequences and length of PCR/RFLP products
Polymorphism Primer sequence*
GSTM1 null polymorphism F: 5′-GAACTCCCTGAAAAGCTAAAGC-
R: 5′-GTTGGGCTCAAATATACGGTGG-
GSTT1 null polymorphism F: 5′-TTCCTTACTGGTCCTCACATCTC-3
R: 5′-TCACCGGATCATGGCCAGCA-3′
ALB (positive control) F: 5′-GCCCTCTGCTAACAAGTCCTA′-3
R: 5′-GCCCTAAAAAGAAAATCGCCAA
GSTP1 A313G F: 5′-CCAGTGACTGTGTGTTGATC-3′
R: 5′-CAACCCTGGTGCAGATGCTC-3′
UGT1A1 A(TA)nTAA F: 5′-GTCACGTGACACAGTCAAAC-3′
R: 5′-TTTGCTCCTGCCAGAGGTT-3′
SULT1A1 G638A F: 5′-GTTGGCTCTGCAGGGTTTCTAGG
R: 5′-CCCAAACCCCCTGCTGGCCAGC
*F – forward primer, R – reverse primer.Primer sequences (Table 1) have been previously de-
scribed by Monaghan et al. [11]. PCR products were then
subjected to electrophoresis in 12% polyacrilamyde gel. A
fragment of 98 bp corresponded to the wild type allele,
100 bp – the seven repeat allele (Figure 1D).
Genotyping results were confirmed by re-genotyping.
All the results (100%) of the second genotyping were in
agreement with the ones obtained previously.
Statistical analysis
Prior to association analyses, deviation from Hardy-
Weinberg equilibrium (HWE) was tested for each poly-
morphism using a Chi-square test. Relationships between
genotypes and clinicopathological features together with
disease progression were estimated by Pearson‘s Chi-
square test. In cases where >25% of cells had expected
value less than 5, Monte Carlo P values were assessed. Lo-
gistic regression analyses were performed to estimate the
odds ratios (OR) associating different GSTM1, GSTT1,
GSTP1, SULT1A1 and UGT1A1 genotypes with clini-
copathological characteristics and disease progression.
P < 0.05 was considered statistically significant. Associ-
ation analyses and logistic regression were carried out
using SPSS (Statistical Package for the Social Sciences)
version 20.0 statistical software (SPSS Inc., Chicago, IL).
Statistical power was also calculated when a statistically
significant association was found.
Results
Genotype distribution of the study population
In a group of 80 patients studied 48.8% were GSTM1
null and 17.5% were GSTT1 null. The frequencies of
GSTP1 genotypes were as follows: 52.5% AA, 35.0% AG
and 12.5% GG. Regarding SULT1A1 43.8% of cases wereLength of PCR or RFLP product, bp
Wild type allele Polymorphic allele
3′ 215 No product
3′





A-3′ 166; 167 333
ACCC-3′
Figure 1 The electrophoresis results of PCR products and restriction endonuclease digestion. A. PCR products of GSTM1 and GSTT1. Lane
M: DNA Ladder; Lane 1: Negative control (no DNA); Lanes 2, 5, 9, 12: GSTM1 null, GSTT1 present; Lanes 3, 4, 6, 7, 10, 11: GSTM1 present, GSTT1
present; Lane 8: GSTT1 null, GSTM1 present. B. Digestion products of GSTP1. Lane M: DNA Ladder; Lanes 1 and 4: AA; Lane 2: Heterozygous
positive control for digestion; Lane 3: AG; Lane 5: GG; Lane 6: Negative control. C. Digestion products of SULT1A1. Lane M: DNA Ladder; Lane 1:
Negative control; Lane 2: AG; Lane 3: GG; Lanes 4 and 5: AA; Lane 6: Positive control for digestion. D. PCR products of UGT1A1. Lane M: DNA
Ladder; Lane 1: Negative control; Lane 2: 6/6; Lane 3: 6/7; Lanes 4 and 5: 7/7. The DNA ladders are used for approximate sizing of DNA fragments.
The discrepancy between the size of digestion products and DNA ladder fragments in panel B may be due to the different fragment migration in
gel resulting from different GC/AT content. The 41 bp fragment is extremely faint and masked by the tracking dye in panel B.
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typing identified 43.8% 6/6, 42.5% 6/7 and 13.8% of pa-
tients to have 7/7 genotype. The genotypes of GSTP1,
SULT1A1 and UGT1A1 were under HWE. Concerning
GSTM1 and GSTT1, the genotyping assay used in this
study does not distinquish homozygous wild type from
heterozygous individuals, which makes it impossible to
evaluate deviation from HWE.
The associations between genotypes and tumor
characteristics
We aimed to determine the linkage between the geno-
types of genes involved in estrogen metabolism and
clinicopathological characteristics of BC together with
disease progression. The results (presented in Additionalfile 1: Table S2) of the analysis showed a few significant
associations.
There was a statistically significant correlation be-
tween GSTT1 genotype and the presence of disease
progression (P = 0.038). We also determined a signifi-
cant association between SULT1A1 G638A genotype
and HER2 molecular subtype of BC (P = 0.016). As far
as GSTM1, GSTP1 or UGT1A1 genes are concerned
(Additional file 1: Table S2) we did not identify any
significant genotype-phenotype association in our study
(by Pearson’s Chi-square test). Synergistic effect of
combined GSTT1 and GSTM1 genotypes (both null
genotypes versus other genotypes) was also analyzed,
however no statistically significant correlation was
determined.
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Additional analyses were performed to clarify further
the effect of low activity variant allele on BC phenotype
and disease progression. The dominant and recessive
models of each polymorphism are given in Table S3
(see Additional file 1). The results showed SULT1A1
allele A to be significantly associated with HER2 mo-
lecular subtype only in a recessive model (P = 0.006).
As our detection method for GSTM1 and GSTT1 dele-
tions lack the information on heterozygosity, assessing
the models for those polymorphisms was impossible.
Other correlations were non-significant.
The odds ratios
Table 2 presents statistically significant odds ratios deter-
mined by logistic regression analysis. The data indicated
that individuals with GSTT1 null genotype have approxi-
mately 3.5 times higher risk for BC progression than
those with wild type genotype (OR = 3.472, 95% CI
1.043-11.559, P = 0.043). The association remained
statistically significant after adjustment for all the
treatments the patient received. The prevalence of
HER2 BC subtype was significantly higher in individ-
uals with SULT1A1 AA genotype (OR = 19.971, 95% CI
1.716-232.480, P = 0.017) when compared to GG geno-
type. A allele significantly increased the chances of
HER2 molecular subtype tumours only in a recessive
model (OR = 7.996, 95% CI 1.457-43.873, P = 0.017)
but not in a dominant one (P = 0.099).
In addition, logistic regression analysis showed that
GSTP1 AG genotype significantly increased the odds of
positive lymph nodes in comparison to AA genotype
(OR = 2.803, 95% CI 1.049-7.487, P = 0.040), although no
significant association was detected by Pearson Chi-square
test.
In each case of a significant association, statistical
power was calculated and varied between 59.5-97.1%.Table 2 Odds ratios for associations of different
genotypes with breast cancer clinicopathological
features
Genotype Adjusted* odds ratio
(95% Confidence interval)
P value
Odds of disease progress
GSTT1 null genotype versus
present genotype
3.472 (1.043-11.559) 0.043
Odds of positive lymph nodes
GSTP1 AG versus AA 2.803 (1.049-7.487) 0.040
Odds of HER2 molecular subtype
SULT1A1 AA versus GG 19.971 (1.716-232.480) 0.017
SULT1A1 AA versus AG + GG 7.996 (1.457-43.873) 0.017
*Adjusted for age at diagnosis.
Only statistically significant associations are shown.Discussion
To our knowledge this is the first study investigating the
association between genotypes in five major estrogen
metabolizing genes and BC characteristics. We assessed
the relationships between GSTM1, GSTT1, GSTP1,
SULT1A1, UGT1A1 genotypes and BC phenotype together
with disease progression. Our study found significant asso-
ciations between polymorphisms in BC susceptibility genes
and clinicopathological features of BC, as well as disease
progression, with corresponding statistical power between
59.5-97.1%. These findings could provide useful prognostic
information.
We identified a statistically significant correlation be-
tween GSTT1 null allele and disease progression, which
remained statistically significant after adjustment for the
treatments the patient received (P = 0.025). However,
other associations of GSTT1 and tumor characteristics
were non-significant. Pongtheerat and colleagues [12]
also analyzed the linkage between GSTT1 deletion and
lymph node involvement, status of estrogen, progester-
one and HER2 receptors, and tumor size. This study was
performed in Thai BC patients and no significant associ-
ation was reported.
Futhermore, our study showed that heterozygous
GSTP1 A313G genotype increases the chances of lymph
node involvement if compared with AA genotype. Inter-
estingly, homozygous GG genotype was not significantly
related to lymph node status in our study. Bearing in
mind the G allele is the low activity allele we anticipated
the homozygous variant genotype to associate with posi-
tive lymph nodes. The absence of significant association
might be due to a small number of individuals with GG
genotype in our study. After all, Nedelcheva Kristensen
et al. [13] found G allele to be associated with negative
lymph nodes in a dominant model (AG + GG versus
AA). However, Pongtheerat et al. [12] and Romero
et al. [14] reported no correlation between GSTP1
A313G polymorphism and lymph node status in Thai
and Spain BC populations, respectively. Prognostic
value of axillary node status together with inconsistency
between the data about G allele effect on lymph node
metastasis points out to a necessity of larger studies in the
future.
Regarding GSTP1 genotype other correlations were
non-significant in our study, which is consistent with
Romero and colleagues report [14]. However, Pongtheerat
and his group [12] identified a relation between GSTP1
A313G polymorphism and PR status. Since PR expression
has a prognotic value and is related to favourable progno-
sis, further investigation is needed to clarify the effect of
GSTP1 on tumor characteristics.
We revealed that AA genotype of SULT1A1 increased
the odds of HER2 molecular subtype of BC. HER2 amplifi-
cation/overexpression is a strong prognostic factor for
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BC is related to poor prognosis of the patients. Our find-
ing that SULT1A1 AA genotype encoding the low activity
enzyme is associated with a poor prognosis factor is in
agreement with a general notion that a high sulfation cap-
acity is protective against proliferative effects of estrogens.
Other associations between SULT1A1 and clinicopath-
ological BC characteristics were not detected in our
study. Shatalova et al. [15] also did not find any associ-
ation between SULT1A1 genotype and BC phenotype,
comprising tumour size and lymph node metastasis in
BC patients of Russian ancestry. However, Han et al.
[16] announced that Chinese carriers of A allele had a
significantly higher number of positive lymph nodes,
thus, arising discussion on topic.
According to our results GSTM1 null deletion does
not play an important role on BC phenotype and disease
progression. The results are in agreement with Medeiros
et al. [17], Romero et al. [14] and Lizard-Nacol et al. [18]
reports, which also did not show the associations regard-
ing GSTM1 deletion. However, Nedelcheva Kristensen
et al. [13] reported that combined GSTM1 null and
GSTT1 null genotype correlated with positive lymph node
status. Our study did not determine any association of
combined GSTM1 null and GSTT1 null genotype with BC
phenotype or disease progression.
Furthermore, UGT1A1 gene did not reveal any sig-
nificant association with studied tumor characteristics.
Shatalova et al. [19] also investigated the relationship
between UGT1A1 A(TA)nTAA polymorphism and
tumour size and grade but did not find any linkage.
However, another study by Shatalova and colleagues
[15] reavealed the association between this polymorph-
ism and tumour size in Russian BC cases which en-
courages futher investigation.
Generally, the observed associations of lack of/ low
enzyme activity with poor BC prognosis in our study
are in agreement with a perception that lower effi-
ciency of estrogen metabolite elimination leads to a
more intense estrogenic stimulation of cancer tissue
growth. Nonetheless, our study has some limitations.
One of the limitations is small sample size. Larger co-
hort would allow conducting more precise subgroup
analyses by different BC characteristics. Short follow-
up period of our patients is another limitation of the
study.
Conclusions
In conclusion, our findings suggest that GSTT1 null
genotype and SULT1A1 G638A AA genotype could be
useful genetic markers for breast cancer prognosis.
Further analyses on larger sample size are needed to
highlight the effect of GSTP1 G allele on breast cancer
prognosis.Additional file
Additional file 1: Table S2. Association between genotype of each
polymorphism with clinicopathological features of breast cancer. Table S3.
Association between variant of each polymorphism (dominant and
recessive models) with clinicopathological features of breast cancer.
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